Aptagen, LLC
S132B-C22 (ID# 7920)
RNA
Botulinum Neuroxin Type A (BoNT/A)
Protein
0.8 nM (reported value)
PBS, pH 7.4, 300mM NaCl, 3mM MgCl2, 5mM DTT, 1mg/ml BSA, 0.2% Tween, 1mg/ml heparin
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
rGprAprCprAprGprCprGpUrGprCprCpUrAprGprAprAprGpUrCprCprAprAprGprCpUUrAprAprApUrAprAprCprCprAprCprGprCpUrCprGprAprCprAprAprGprCp
40
12930.02
395100
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Tzuu-Wang Chang, Michael Blank, Pavithra Janardhanan, Bal Ram Singh, Charlene Mello, Michael Blind, Shuowei Cai, "In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin" Biochemical and Biophysical Research Communications 396 (2010) 854ƒ??860.
Have your aptamer oligo synthesized
ORDER NOW



We are always looking for ways to improve. Please tell us what you think.